3rd Quarter - Report
NOVOCURE INC. for NOVOCURE INC.
Firm
Client
Income
—
Expenses
$140,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
General Medicare Issues. H.R.1691 - Ensuring Patient Access to Critical Breakthrough Products Act of 2023.
Foreign entity interest: Novocure GmbH, Novocure Luxembourg S.a.r.l. (who owns 100% of Novocure GmbH) and NovoCure Limited (who owns 100% of Luxembourg S.a.r.l.), identified on filer's Registration Statement (LD-1), as its parent organization, has an interest in the listed issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHERINE MEYER | Senior Policy Advisor, Office of House Republican Leader Kevin McCarthy; Deputy Health Policy Director, Senate Finance Committee; Health Policy Advisor, Senator Orrin Hatch; Sr. LA, Congressman Erik Paulsen; LA, Congressman Jeff Fortenberry |
| ZARIA SMITH | — |
| LAURA WINTERS New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.